Skip to content

Etravirine: severe rash warning added to prescribing info

Risk of kidney problems similar for tenofovir and alternative drugs

IRIS responsible for low number of deaths in patients starting HIV treatment in Uganda

More evidence of bone loss with HIV therapy, more confusion over the role of specific drugs

ddI treatment sole risk factor for noncirrhotic portal hypertension

Low bone mineral density in Botswana PrEP trial participants raises concerns

Two new analyses add to abacavir cardiovascular risk debate

Stepped doses reduce incidence and severity of efavirenz-related side-effects

HIV treatment and traditional risk factors causing hardening of the arteries